Correlation between flow cytometry and histologic findings: ten year experience in the investigation of lymphoproliferative diseases

Bezerra, Alanna Mara Pinheiro Sobreira; Pasqualin, Denise da Cunha; Guerra, João Carlos de Campos; Colombini, Marjorie Paris; Velloso, Elvira Deolinda Rodrigues Pereira; Silveira, Paulo Augusto Achucarro; Mangueira, Cristóvão Luis Pitangueiras; Kanayama, Ruth Hissae; Nozawa, Sonia Tsukasa; Correia, Rodolfo Patussi; Apelle, Ana Carolina; Pereira, Welbert Oliveira; Garcia, Rodrigo Gobbo; Bacal, Nydia Strachman

doi:10.1590/s1679-45082011ao2027

Cited by 5 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1 In a comparison of the detection of marker expression by IHC and flow cytometry in a cohort containing more varied diagnoses, including B-cell and T-cell lymphomas and benign lymphoproliferations, a higher concordance was found for the T-cell markers than for the B-cell markers, with the results for κ and λ light chains having the lowest concordance. 9 A study comparing the diagnoses reached using flow cytometry immunophenotyping vs histology/IHC in lymphoma and lymphoproliferative disease found 80% agreement in 9 of 11 disease groups, with the diagnosis of Hodgkin lymphoma being the most discordant; 8 however, this study did not compare the detection or use of specific markers.…”

Section: Discussionmentioning

confidence: 77%

“…In addition, IHC may provide important information regarding the expression of nuclear or cytoplasmic markers that cannot be detected by flow cytometry without prior membrane permeabilization. There have been only a few studies of the correlation between flow cytometry and IHC findings for human leukemia, although studies comparing the results obtained with these techniques have been performed for lymphoma and lymphoproliferative disease, 8,9 chronic B-cell leukemia and lymphoma, 1 and acute lymphoblastic leukemia. 2,4 Most of these studies evaluated how well IHC performed in detecting the same markers used in flow cytometry, but few evaluated and/or compared the diagnosis of the same lymphoma by IHC and flow cytometry.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Immunophenotyping of Murine Precursor B-Cell Leukemia/Lymphoma: A Comparison of Immunohistochemistry and Flow Cytometry

et al. 2019

View full text Add to dashboard Cite

In humans and in mouse models, precursor B-cell lymphoblastic leukemia (B-ALL)/lymphoblastic lymphoma (B-LBL) can be classified as either the pro-B or pre-B subtype. This is based on the expression of antigens associated with the pro-B and pre-B stages of B-cell development. Antigenic markers can be detected by flow cytometry or immunohistochemistry (IHC), but no comparison of results from these techniques has been reported for murine B-ALL/LBL. In our analysis of 30 cases induced by chemical or viral mutagenesis on a WT or Pax5+/– background, 18 (60%) were diagnosed as pro-B by both flow cytometry and IHC. Discordant results were found for 12 (40%); 6 were designated pro-B by IHC and pre-B by flow cytometry and the reverse for the remaining 6 cases. Discordance occurred because different markers were used to define the pro-B–to–pre-B transition by IHC vs flow cytometry. IHC expression of cytoplasmic IgM (μIgM) defined the pre-B stage, whereas the common practice of using CD25 as a surrogate marker in flow cytometry was employed here. These results show that CD25 and μIgM are not always concurrently expressed in B-ALL/LBL, in contrast to normal B-cell development. Therefore, when subtyping B-ALL/LBL in mice, an IHC panel of B220, PAX5, TdT, c-Kit/CD117, CD43, IgM, and ΚLC should be considered. For flow cytometry, cytoplasmic IgM may be an appropriate marker in conjunction with the surface markers B220, CD19, CD43, c-Kit/CD117, BP-1, and CD25.

show abstract

Section: Discussionmentioning

confidence: 77%

mentioning

confidence: 99%

Immunophenotyping of Murine Precursor B-Cell Leukemia/Lymphoma: A Comparison of Immunohistochemistry and Flow Cytometry

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Bezerra et al 16 e Boyd et al 4 , por sua vez, discutem que, em várias situações, é somente pela associação dos resultados da citometria de fluxo com os achados histopatológicos, imuno-histoquímicos e moleculares que é possível diagnosticar e diferenciar processos reacionais de neoplasias e, ainda, subclassificar as várias DLPCB.…”

Section: Discussionunclassified

Análise dos Critérios Imunofenotípicos por Citometria de Fluxo para Definição das Doenças Linfoproliferativas Crônicas de Células B

Junior¹,

Fonseca²,

Paixão³

et al. 2023

Rev. Bras. Cancerol.

View full text Add to dashboard Cite

Introdução: A citometria de fluxo é uma metodologia importante para o diagnóstico das doenças linfoproliferativas crônicas de células B (DLPCB), contudo, por vezes, o citometrista não encontra subsídios suficientes para a definição exata da entidade patológica envolvida. Objetivo: Analisar os laudos emitidos a pacientes com doenças linfoproliferativas crônicas (DLPC) atendidos em um laboratório particular de Belém-PA, segundo os critérios de classificação estabelecidos pelos estudos de Matutes et al. e Craig e Foon. Método: Estudo retrospectivo com laudos de pacientes que realizaram imunofenotipagem por citometria de fluxo para diagnóstico de DLPCB no período entre setembro de 2015 a dezembro de 2019. Resultados: Depois de aplicados os critérios de Matutes et al. e Craig e Foon para os laudos analisados, observou-se concordância em: 45,24% casos de leucemia linfoide crônica de células B/linfoma linfocítico de pequenas células B; 14,29% casos de linfoma folicular; 4,76% casos de leucemia de células pilosas; e 21,43% de casos definidos como “outras DLPCB não classificáveis por citometria de fluxo”. Entretanto, o teste de hipóteses de Hotelling (p=0,0409) mostrou haver diferença estatística para a definição das DLPCB segundo os critérios aplicados. Conclusão: Os resultados ressaltam que, mesmo sendo a citometria de fluxo importante para a caracterização das DLPCB, por vezes, o citometrista necessita incluir no laudo a categoria “outras doenças linfoproliferativas crônicas de células B não classificadas por citometria de fluxo” para induzir o prescritor a solicitar mais exames complementares.

show abstract

Value of multi-parameter flow cytometry immunophenotyping in T/NK-cell neoplasms in cytology specimens: A retrospective study in Chinese patients

Zheng

Wan

Gui

et al. 2020

Pathology - Research and Practice

View full text Add to dashboard Cite

Correlation between flow cytometry and histologic findings: ten year experience in the investigation of lymphoproliferative diseases

Abstract: Flow cytometry adds to the results of morphologic and immunohistochemical studies, facilitating a rapid and accurate diagnosis of lymphoproliferative diseases.

Cited by 5 publications

References 25 publications

Immunophenotyping of Murine Precursor B-Cell Leukemia/Lymphoma: A Comparison of Immunohistochemistry and Flow Cytometry

Immunophenotyping of Murine Precursor B-Cell Leukemia/Lymphoma: A Comparison of Immunohistochemistry and Flow Cytometry

Análise dos Critérios Imunofenotípicos por Citometria de Fluxo para Definição das Doenças Linfoproliferativas Crônicas de Células B

Value of multi-parameter flow cytometry immunophenotyping in T/NK-cell neoplasms in cytology specimens: A retrospective study in Chinese patients

Contact Info

Product

Resources

About